Serina Therapeutics Files 8-K: Officer/Director Changes & More

Ticker: SER · Form: 8-K · Filed: May 22, 2025 · CIK: 1708599

Serina Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySerina Therapeutics, Inc. (SER)
Form Type8-K
Filed DateMay 22, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, officer-changes, director-changes, bylaws

TL;DR

Serina Therapeutics 8-K: Board shakeup, officer changes, and bylaws updated. Big governance news.

AI Summary

Serina Therapeutics, Inc. filed an 8-K on May 22, 2025, reporting on several key events. These include the departure of directors or certain officers, the election of directors, the appointment of certain officers, and updates to compensatory arrangements. The filing also covers amendments to articles of incorporation or bylaws, changes in fiscal year, and Regulation FD disclosures, along with financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate governance and operational updates for Serina Therapeutics, potentially impacting its strategic direction and investor relations.

Risk Assessment

Risk Level: medium — Changes in directors, officers, and bylaws can signal shifts in company strategy or internal dynamics, warranting closer investor scrutiny.

Key Players & Entities

  • Serina Therapeutics, Inc. (company) — Registrant
  • May 22, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 82-1436829 (ein) — IRS Employer Identification No.
  • 601 Genome Way, Suite 2001 Huntsville, Alabama 35806 (address) — Principal Executive Offices
  • AgeX Therapeutics, Inc. (company) — Former Company Name
  • June 6, 2017 (date) — Date of Name Change

FAQ

Who specifically departed from Serina Therapeutics' board or officer positions?

The filing indicates the departure of directors or certain officers but does not name the individuals in this section of the provided text.

Were there any new directors or officers appointed?

Yes, the filing explicitly mentions the election of directors and the appointment of certain officers.

What specific amendments were made to the articles of incorporation or bylaws?

The filing notes amendments to articles of incorporation or bylaws, but the specific details of these amendments are not provided in this excerpt.

Does the filing include any updates on Serina Therapeutics' financial statements?

Yes, the filing indicates that financial statements and exhibits are included as part of the report.

What is the former name of Serina Therapeutics, Inc. and when did the name change occur?

The former name was AgeX Therapeutics, Inc., and the date of the name change was June 6, 2017.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 22, 2025 regarding Serina Therapeutics, Inc. (SER).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.